New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma

COPD is a complex disease combining inTammatory processes and structural changes to lung tissues, affecting more than 10%of theworld population over the age of 40 years. Alveolarmacrophages are known to play a critical role in the pathophysiology of the disease by secreting pro-inTammatory cytokines such as TNF-α and CXCL8. Corticosteroids arewidely-used in the clinic for the treatment of COPD, however their therapeutic beneSt is limited by a steroid-refractory phenotype.1 The objective of the present study was to identify topical dual p38α,γ and HCK kinase inhibitors for the treatment of corticosteroid resistant COPD and asthma.

Download Poster

Poster download form with organisation field
Invalid email address provided.
Please only use your business email address.